Ketamine intranasal - Hospira

Drug Profile

Ketamine intranasal - Hospira

Alternative Names: Ereska; Intranasal ketamine; PMI-100; PMI-150

Latest Information Update: 01 Feb 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Innovative Drug Delivery Systems
  • Developer Hospira
  • Class Analgesics; Antidepressants; Cyclohexanes; General anaesthetics; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Acute pain
  • Discontinued Cancer pain

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 10 Jan 2012 Hospira terminates the phase III trial in Cancer pain (breakthrough pain) in USA (NCT00492388)
  • 31 Dec 2010 No development reported - Phase-III for Acute pain in Europe (Intranasal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top